Arthneeti
All Q2 FY27 results →
F

FDC Ltd

Q2 FY27Pharmaceuticals & Biotechnology

FDC Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Price₹354
Market cap₹5.8K Cr
P/E18.7
Updated28 Oct 2026
Read2 min read

FDC Ltd Q2 FY27 key numbers

Revenue
Quarterly revenue from operations (consolidated) for Q2 ended September 30, 2026: Rs. 57,214 lakhs, up from Rs. 47,303 lakhs in Q2 September 2025 (approximately 20.9% YoY growth).

As stated in FDC Ltd's Q2 FY27 results statement · published 28 Oct 2026. Reported figures, not investment advice.

Based on FDC Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Quarterly revenue from operations (consolidated) for Q2 ended September 30, 2026: Rs. Quarterly EBITDA: ₹19,921 lakhs, up 21% YoY from ₹16,559 lakhs (Page 14). - Quarterly Operating Margin: 32.6%, increased from 30.3% YoY (Page 14). - Quarterly Profit After Tax (PAT): ₹15,030 lakhs, up 39% YoY from ₹10,838 lakhs (Page 10). - Explicit Margin Outlook: The presentation states an expectation to maintain strong operating margins around the current level (approx.

From FDC Ltd's Q2 FY27 earnings-call transcript · updated 28 Oct 2026.

Revenue & Sales Performance

  • Quarterly revenue from operations (consolidated) for Q2 ended September 30, 2026: Rs. 57,214 lakhs, up from Rs. 47,303 lakhs in Q2 September 2025 (approximately 20.9% YoY growth).
  • Consolidated total income for the quarter: Rs. 59,008 lakhs vs. Rs. 53,011 lakhs in Q2 September 2025.
  • Standalone revenue from operations for Q2 September 2026: Rs. 55,279 lakhs, compared to Rs. 61,174 lakhs for Q2 September 2025 (a decline of about 9.7% YoY).

2 more points from FDC Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

- **Quarterly EBITDA**: ₹19,921 lakhs, up 21% YoY from ₹16,559 lakhs (Page 14). - **Quarterly Operating Margin**: 32.6%, increased from 30.3% YoY (Page 14). - **Quarterly Profit After Tax (PAT)**: ₹15,030 lakhs, up 39% YoY from ₹10,838 lakhs (Page 10). - **Explicit Margin Outlook**: The presentation states an expectation to maintain strong operating margins around the current level (approx. 32-33%) through product mix optimization and cost control initiatives (Page 15). All figures are according to the financials and notes as presented without adjustment.

Capital Expenditure Plans

See what FDC Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what FDC Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what FDC Ltd said on order book & pipeline — free account, 30 seconds.

FDC Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹572 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What FDC's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sudeep Pharma Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations:** Rs 196.7 crore . Key investor presentation takeaways from Sudeep Pharma Ltd's Q2 FY27 investor presentation — and how it rank

  • Jagsonpal Pharmaceuticals Ltd (Q2 FY27)

    Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY . Key investor presentation takeaways from Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation — and

  • Zota Health Care Ltd (Q2 FY27)

    Revenue from Operations for Q2FY27 is ₹19,933.14 lakhs, up 54.58% YoY from ₹12,894.82 lakhs in Q2FY26. Key investor presentation takeaways from Zota Health Care

  • Indoco Remedies Ltd (Q2 FY27)

    Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year. Key results statement

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

FDC Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were FDC Ltd Q2 FY27 results?

Quarterly revenue from operations (consolidated) for Q2 ended September 30, 2026: Rs. Quarterly EBITDA: ₹19,921 lakhs, up 21% YoY from ₹16,559 lakhs (Page 14). - Quarterly Operating Margin: 32.6%, increased from 30.3% YoY (Page 14). - Quarterly Profit After Tax (PAT): ₹15,030 lakhs, up 39% YoY from ₹10,838 lakhs (Page 10). - Explicit Margin Outlook: The presentation states an expectation to maintain strong operating margins around the current level (approx.

What is FDC Ltd share price analysis?

FDC Ltd currently shows a neutral. The stock trades at a P/E of 18.7 with a market cap of ₹5,760 Cr. Investors should review the full earnings analysis for detailed insights.

Keep FDC Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.